IXT-010

IXT-010 is an investigational inhaled therapeutic being developed by invoX Pharma for the treatment of Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The drug is administered via the proprietary Softhaler® dry powder inhalation (DPI) platform, which is designed to deliver medications efficiently to the lungs independent of the patient's inspiratory effort. While the specific active ingredient and molecular target have not been publicly disclosed, the IXT-010 program is part of a broader pipeline utilizing the Softhaler technology to deliver a range of modalities, including small molecules and biological agents such as peptides or nucleic acids.